Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
107M
-
Number of holders
-
21
-
Total 13F shares, excl. options
-
3.09M
-
Shares change
-
+108K
-
Total reported value, excl. options
-
$4.86M
-
Value change
-
+$176K
-
Put/Call ratio
-
0.02
-
Number of buys
-
12
-
Number of sells
-
-4
-
Price
-
$1.57
Significant Holders of SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) as of Q2 2023
29 filings reported holding SLS - SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share as of Q2 2023.
SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) has 21 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3.09M shares
of 107M outstanding shares and own 2.9% of the company stock.
Largest 10 shareholders include Alyeska Investment Group, L.P. (1.25M shares), VANGUARD GROUP INC (947K shares), BlackRock Inc. (283K shares), GEODE CAPITAL MANAGEMENT, LLC (188K shares), Equitable Holdings, Inc. (135K shares), STATE STREET CORP (97.1K shares), NORTHERN TRUST CORP (39.4K shares), Opus Capital Group, LLC (31K shares), Prosperity Financial Group, Inc. (29.8K shares), and WELLS FARGO & COMPANY/MN (16.3K shares).
This table shows the top 21 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.